StockData

Astrana Health vs ICF International

ASTH and ICFI side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASTH and ICFI compare

Astrana Health is the larger company, worth 1.3 times as much as ICF International ($1.8B against $1.4B).

On earnings, ICF International is cheaper: it trades at 16.4× trailing earnings, against 40.1× for Astrana Health.

Astrana Health grew revenue faster over the last twelve months (58.9% versus −7.9% for ICF International).

ICF International keeps more of each dollar of sales as profit, with a net margin of 4.9% compared with 1.1% at Astrana Health.

ICF International pays a dividend yielding 0.71%; Astrana Health does not pay one.

ICF International scores higher on the StockData Score (20 against 8 for Astrana Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASTHICFI
Size and price
Market cap$1.8B$1.4B
Share price$32.87$79.42
Change, 1 year50.0%0.23%
Change, 5 years−65.2%−20.8%
Beta (5Y)1.001.41
Employees3,0008,400
StockData Score
Total score820 (better)
Valuation score16 (better)
Growth score4 (better)2
Performance score24 (better)
Health score14 (better)
Dividend score04 (better)
Valuation
P/E40.1×16.4× (better)
P/S0.5× (better)0.8×
P/B2.2×1.4× (better)
EV/EBITDA14.5×9.3× (better)
P/FCF19.4×7.2× (better)
PEG–1.21
FCF yield5.2%13.9% (better)
Fair value$26.41$119.66
Margin of safety−24.5%33.6% (better)
Growth
Revenue growth (TTM)58.9% (better)−7.9%
Revenue growth, 5Y average35.9% (better)4.4%
Net income growth (TTM)60.5% (better)−17.8%
EPS growth (TTM)57.7% (better)−16.0%
EPS growth, 5Y average−14.6%11.5% (better)
Profitability
Gross margin10.5%37.2% (better)
Operating margin2.6%7.8% (better)
Net margin1.1%4.9% (better)
FCF margin2.5%10.9% (better)
Return on equity5.1%8.6% (better)
Return on invested capital6.0%7.7% (better)
Financial health
Debt / equity1.130.39 (better)
Net debt / EBITDA3.282.05 (better)
Interest coverage1.5×4.9× (better)
Current ratio1.231.39 (better)
Altman Z-score2.78 (better)2.66
Piotroski F-score47 (better)
Dividends and buybacks
Dividend yield–0.71%
Payout ratio4.6%11.6%
Years of dividend growth–0
Dividend growth, 5Y average–0.00%
Buyback yield0.97%3.2% (better)
Shareholder yield0.97%3.9% (better)
Ownership
Held by institutions57.7%102%
Held by insiders30.7%1.8%
Insider net buying, 12 months–−$1.4M
Short interest, % of float7.8%3.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.